Research–led, global pharmaceutical company Glenmark Pharmaceuticals Inc., USA (Glenmark) (BSE: 532296) (NSE: GLENMARK) announced on Thursday that it has received approval from the United States Food & Drug Administration (US FDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC).
The product determined by the FDA to be bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), of Alcon Laboratories, Inc. It is to be distributed in the United States by Glenmark Therapeutics Inc., USA. The Nielsen syndicated data for the latest 52 weeks' period ending 22 February 2025 revealed that the product achieved annual sales of approximately USD50.7m.
Marc Kikuchi, president & Business Head, North America said, 'We are pleased to continue to expand our OTC ophthalmic portfolio. The addition of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% highlights our commitment to meeting market needs and providing quality over-the-counter solutions for our customers.'
Intelligent Bio Solutions strengthens IP with sixth US patent ahead of 2025 market entry
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Ionis announces partnership expansion with Sobi for global olezarsen commercialisation
Nyxoah receives FDA Approvable Letter for Genio system
Palatin Technologies' PL7737 granted US FDA orphan drug designation
Benuvia Operations receives five-year contract from NIDA
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Sanofi's tolebrutinib receives FDA priority review for multiple sclerosis treatment
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Agilent xCELLigence technology Supports FDA Approval of AUCATZYL
Journey Medical launches Emrosi for treatment of rosacea
Everest Medicines' EVM14 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab